Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.
about
Molecular strategies to inhibit HIV-1 replicationInteractions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients.Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblastsFailure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactionsInhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralizationHerpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection.Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same siteHuman immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures.
P2860
Q24799813-AC8851EE-1D73-4D48-A966-84EC94E4836BQ33781055-3EEB1804-13B0-42F0-8199-18B5EA69DEA4Q33852361-26462550-0126-4F22-8E74-B5965C7E288CQ34078508-EB989B1F-0DBD-4A44-866A-018CE7AB3C99Q34342119-F4D26B63-0237-4D07-80EB-3131AD4A6DAFQ34396833-8A521EEE-778E-4C51-915A-32EC3F810D96Q34983331-C4080740-3928-4BF3-A200-F3F9D610CCBAQ35933555-ACB7B044-00A2-4D48-8C93-A19396DB1BC9Q36541239-FE6DABFA-9874-4A13-9E40-01A1178A71DEQ36837815-8A4599F7-1A2B-4E95-81F5-13E22970AE3FQ37456642-CDC5D74E-6D63-4291-A03E-1AC8BE937029Q39699375-F35B761B-BA30-49A4-9A4F-2C431F3F2A78Q39700360-A855C623-4FE0-4971-BC2D-62D4397B0503Q42797346-871DD6F8-BFBA-48E0-AE81-0A99210AD925
P2860
Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antibody-mediated neutralizati ...... f the mechanism of inhibition.
@ast
Antibody-mediated neutralizati ...... f the mechanism of inhibition.
@en
type
label
Antibody-mediated neutralizati ...... f the mechanism of inhibition.
@ast
Antibody-mediated neutralizati ...... f the mechanism of inhibition.
@en
prefLabel
Antibody-mediated neutralizati ...... f the mechanism of inhibition.
@ast
Antibody-mediated neutralizati ...... f the mechanism of inhibition.
@en
P2093
P2860
P1433
P1476
Antibody-mediated neutralizati ...... f the mechanism of inhibition.
@en
P2093
P2860
P304
P356
10.1128/JVI.75.5.2235-2245.2001
P577
2001-03-01T00:00:00Z